摘要
目的探讨诺维本(NVB)与异环磷酰胺(IFO)联合作为二线方案治疗复发小细胞肺癌(SCLC)的疗效及毒副作用。方法采用NVB加IFO(NI)方案治疗复发SCLC患者36例。化疗剂量:NVB25mg/m^2 d1、8;IFO1.2~1.5g/m^2d2~4,配合mesna解毒,同时水化。每3周重复,至少治疗2周期。结果共完成92周期,中位数2周期。无CR病例,PR12例,SD17例,PD7例,总有效率33.33%。主要毒副作用是骨髓抑制、恶心呕吐及静脉炎。白细胞减少为55.55%(20/36),其中Ⅲ+Ⅳ度为5.55%(2/36);恶心呕吐及静脉炎发生率分别为75.00%(27/36)及38.89%(14/36),均为Ⅰ、Ⅱ度。结论NI方案治疗复发小细胞肺癌疗效较好,毒副作用可耐受,有较好的临床应用价值。
Objective To evaluate the efficacy and toxicity of combined chemotherapy with navelbine (NVB) plus ifosfamide (IFO) in the second-line treatment of recurrent small cell lung cancer (SCLC). Methods Thirty - six patients with recurrent SCLC were enrolled for this study. Navelbine were administered 25mg/m^2 on day 1、8, ifosfamide 1.2 - 1.5g/m^2 on day 1-4 which was recycled every 3 weeks and with at least 2 cycles. Results 92 cycles of the chemotherapy were completed and median cycles of the treatment were 2. Among them, 12 patients achieved partial response, 17 patients achieved stable diseases and 7 patients achieved progressive diseases. The overall response rate is 33.33% (12/36). The main toxicities were myelosuppression, nausea/vomiting and phlebitis. Leukopenia accounted for 55.55 % grade Ⅲ+Ⅳ was 5.55 %, nausea/vomiting accounted for 75.00% and phlebitis accounted for 38.89%, which were all grade Ⅰ and Ⅱ Conclusion The schedule of navelbine and ifosfamide in the second - line treatment of recurrent SCLC has good chinical efficancy and tolerability, the regimen could be quite clinically valuable.
出处
《癌症进展》
2006年第1期69-72,68,共5页
Oncology Progress
关键词
小细胞肺癌
诺维本
异环磷酰胺
二线化疗
small cell lung cancer navelbine ifosfamide second- line treatment